Kleiner Perkins Caufield & Byers
2750 Sand Hill Road
9 articles with Kleiner Perkins Caufield & Byers
Ribometrix closed on a Series A financing worth $30 million. The round was led by M Ventures, with participation of new investors Amgen Ventures, Pappas Capital and Illumina Ventures.
FLX Bio Announces First Patient Dosed With FLX475, a Best-in-Class CCR4 Inhibitor for the Treatment of Multiple Cancers
FLX Bio, Inc., a clinical-stage, biopharmaceutical company, today announced that the first patient has been treated in its Phase 1/2 clinical trial of FLX475 in patients with various advanced cancers.
There is a new player in the southern California biotech industry. New venture firm Westlake Village BioPartners launched with a $320 million fund and a leadership well familiar with the ins and outs of the biotech and pharma world.
Kleiner Perkins Caufield & Byers Launches Two Funds; $600M Technology And Life Science, $200M Pandemic And Bio Defense
Kleiner Perkins Caufield & Byers Forms $600 Million KPCB XII Fund, Announces $100 Million Greentech Initiative